Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 507 entries
Sorted by: Best Match Show Resources per page
Interferon beta (IFN-β) treatment exerts potential neuroprotective effects through neurotrophic factors and novel neurotensin/neurotensin high affinity receptor 1 pathway.

Neural regeneration research

Wang Q, Mao-Draayer Y.
PMID: 26889174
Neural Regen Res. 2015 Dec;10(12):1932-3. doi: 10.4103/1673-5374.169636.

No abstract available.

Cite
Wang Q, Mao-Draayer Y. Interferon beta (IFN-β) treatment exerts potential neuroprotective effects through neurotrophic factors and novel neurotensin/neurotensin high affinity receptor 1 pathway. Neural Regen Res. 2015;10(12):1932-3doi: 10.4103/1673-5374.169636.
Wang, Q., & Mao-Draayer, Y. (2015). Interferon beta (IFN-β) treatment exerts potential neuroprotective effects through neurotrophic factors and novel neurotensin/neurotensin high affinity receptor 1 pathway. Neural regeneration research, 10(12), 1932-3. https://doi.org/10.4103/1673-5374.169636
Wang, Qin, and Mao-Draayer, Yang. "Interferon beta (IFN-β) treatment exerts potential neuroprotective effects through neurotrophic factors and novel neurotensin/neurotensin high affinity receptor 1 pathway." Neural regeneration research vol. 10,12 (2015): 1932-3. doi: https://doi.org/10.4103/1673-5374.169636
Wang Q, Mao-Draayer Y. Interferon beta (IFN-β) treatment exerts potential neuroprotective effects through neurotrophic factors and novel neurotensin/neurotensin high affinity receptor 1 pathway. Neural Regen Res. 2015 Dec;10(12):1932-3. doi: 10.4103/1673-5374.169636. PMID: 26889174; PMCID: PMC4730810.
Copy Download .nbib Format: NLM
Efficacy of interferon-beta plus ribavirin combination treatment on the development of hepatocellular carcinoma in Japanese patients with chronic hepatitis C.

Hepatology research : the official journal of the Japan Society of Hepatology

Ikezaki H, Nomura H, Furusyo N, Ogawa E, Kajiwara E, Takahashi K, Kawano A, Maruyama T, Tanabe Y, Satoh T, Nakamuta M, Kotoh K, Azuma K, Dohmen K, Shimoda S, Hayashi J.
PMID: 26189962
Hepatol Res. 2016 Mar;46(3):E174-80. doi: 10.1111/hepr.12555. Epub 2015 Sep 02.

AIM: Although there is much evidence of an antitumor effect of pegylated interferon (IFN)-α-based treatment, limited data is available about that of IFN-β-based treatment. Our goal was to evaluate the impact of IFN-β plus ribavirin (RBV) treatment on the...

Cite
Ikezaki H, Nomura H, Furusyo N, et al. Efficacy of interferon-beta plus ribavirin combination treatment on the development of hepatocellular carcinoma in Japanese patients with chronic hepatitis C. Hepatol Res. 2015;46(3):E174-80doi: 10.1111/hepr.12555.
Ikezaki, H., Nomura, H., Furusyo, N., Ogawa, E., Kajiwara, E., Takahashi, K., Kawano, A., Maruyama, T., Tanabe, Y., Satoh, T., Nakamuta, M., Kotoh, K., Azuma, K., Dohmen, K., Shimoda, S., Hayashi, J. (2016). Efficacy of interferon-beta plus ribavirin combination treatment on the development of hepatocellular carcinoma in Japanese patients with chronic hepatitis C. Hepatology research : the official journal of the Japan Society of Hepatology, 46(3), E174-80. https://doi.org/10.1111/hepr.12555
Ikezaki, Hiroaki, et al. "Efficacy of interferon-beta plus ribavirin combination treatment on the development of hepatocellular carcinoma in Japanese patients with chronic hepatitis C." Hepatology research : the official journal of the Japan Society of Hepatology vol. 46,3 (2016): E174-80. doi: https://doi.org/10.1111/hepr.12555
Ikezaki H, Nomura H, Furusyo N, Ogawa E, Kajiwara E, Takahashi K, Kawano A, Maruyama T, Tanabe Y, Satoh T, Nakamuta M, Kotoh K, Azuma K, Dohmen K, Shimoda S, Hayashi J. Efficacy of interferon-beta plus ribavirin combination treatment on the development of hepatocellular carcinoma in Japanese patients with chronic hepatitis C. Hepatol Res. 2016 Mar;46(3):E174-80. doi: 10.1111/hepr.12555. Epub 2015 Sep 02. PMID: 26189962.
Copy Download .nbib Format: NLM
Production of interferon-beta by NB1-RGB cells cultured on peptide-lipid membranes.

Cytotechnology

Hara M, Takanashi Y, Tuzuki N, Kawakami H, Toma K, Higuchi A.
PMID: 19002924
Cytotechnology. 2003 May;42(1):13-20. doi: 10.1023/A:1026157515032.

Cell growth and production of interferon-beta (IFN-beta) were investigated for normal human skin fibroblast cells (NB1-RGB) cultured on membranes prepared from peptide-lipids containing the arginine-glycine-aspartic acid [Arg-Gly-Asp] (RGD), tyrosine-isoleucine-glycine-serine-arginine [Tyr-Ile-Gly-Ser-Arg] (YIGSR) and arginine-glutamic acid-aspartic acid-valine [Arg-Glu-Asp-Val] (REDV) peptides. Cell...

Cite
Hara M, Takanashi Y, Tuzuki N, et al. Production of interferon-beta by NB1-RGB cells cultured on peptide-lipid membranes. Cytotechnology. 2003;42(1):13-20doi: 10.1023/A:1026157515032.
Hara, M., Takanashi, Y., Tuzuki, N., Kawakami, H., Toma, K., & Higuchi, A. (2003). Production of interferon-beta by NB1-RGB cells cultured on peptide-lipid membranes. Cytotechnology, 42(1), 13-20. https://doi.org/10.1023/A:1026157515032
Hara, Mariko, et al. "Production of interferon-beta by NB1-RGB cells cultured on peptide-lipid membranes." Cytotechnology vol. 42,1 (2003): 13-20. doi: https://doi.org/10.1023/A:1026157515032
Hara M, Takanashi Y, Tuzuki N, Kawakami H, Toma K, Higuchi A. Production of interferon-beta by NB1-RGB cells cultured on peptide-lipid membranes. Cytotechnology. 2003 May;42(1):13-20. doi: 10.1023/A:1026157515032. PMID: 19002924; PMCID: PMC3449508.
Copy Download .nbib Format: NLM
A role for interferon-beta in Guillain-Barré Syndrome?.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy

Créange A.
PMID: 18034551
BioDrugs. 2000 Jul;14(1):1-11. doi: 10.2165/00063030-200014010-00001.

Guillain-Barré syndrome (GBS) is an acute inflammatory demyelinating neuropathy that is associated with long-lasting morbidity and a substantial risk of mortality. The 2 reference treatments, plasma exchange and intravenous immunoglobulins (IVIg), do not change the functional prognosis for the...

Cite
Créange A. A role for interferon-beta in Guillain-Barré Syndrome?. BioDrugs. 2000;14(1):1-11doi: 10.2165/00063030-200014010-00001.
Créange, A. (2000). A role for interferon-beta in Guillain-Barré Syndrome?. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 14(1), 1-11. https://doi.org/10.2165/00063030-200014010-00001
Créange, A. "A role for interferon-beta in Guillain-Barré Syndrome?." BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy vol. 14,1 (2000): 1-11. doi: https://doi.org/10.2165/00063030-200014010-00001
Créange A. A role for interferon-beta in Guillain-Barré Syndrome?. BioDrugs. 2000 Jul;14(1):1-11. doi: 10.2165/00063030-200014010-00001. PMID: 18034551.
Copy Download .nbib Format: NLM
Appropriate use of interferon beta-1a in multiple sclerosis.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy

Jacobs L, Brownscheidle CM.
PMID: 18031126
BioDrugs. 1999 Mar;11(3):155-63. doi: 10.2165/00063030-199911030-00002.

Multiple sclerosis (MS), a chronic inflammatory demyelinating disease of the central nervous system, is the most common crippling neurological disease of young adults in the US. The 2 basic clinical forms of the disease (relapsing and progressive), which can...

Cite
Jacobs L, Brownscheidle CM. Appropriate use of interferon beta-1a in multiple sclerosis. BioDrugs. 1999;11(3):155-63doi: 10.2165/00063030-199911030-00002.
Jacobs, L., & Brownscheidle, C. M. (1999). Appropriate use of interferon beta-1a in multiple sclerosis. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 11(3), 155-63. https://doi.org/10.2165/00063030-199911030-00002
Jacobs, L, and Brownscheidle, C M. "Appropriate use of interferon beta-1a in multiple sclerosis." BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy vol. 11,3 (1999): 155-63. doi: https://doi.org/10.2165/00063030-199911030-00002
Jacobs L, Brownscheidle CM. Appropriate use of interferon beta-1a in multiple sclerosis. BioDrugs. 1999 Mar;11(3):155-63. doi: 10.2165/00063030-199911030-00002. PMID: 18031126.
Copy Download .nbib Format: NLM
A guide to immunotherapy of genital warts: focus on interferon and imiquimod.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy

Czelusta AJ, Evans T, Arany I, Tyring SK.
PMID: 18031142
BioDrugs. 1999 May;11(5):319-32. doi: 10.2165/00063030-199911050-00004.

Genital warts affect at least 1% of sexually active adults. Current therapies are inadequate because they are often painful, may fail to prevent recurrence and transmission of warts, and usually require either surgery or at least application by a...

Cite
Czelusta AJ, Evans T, Arany I, et al. A guide to immunotherapy of genital warts: focus on interferon and imiquimod. BioDrugs. 1999;11(5):319-32doi: 10.2165/00063030-199911050-00004.
Czelusta, A. J., Evans, T., Arany, I., & Tyring, S. K. (1999). A guide to immunotherapy of genital warts: focus on interferon and imiquimod. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 11(5), 319-32. https://doi.org/10.2165/00063030-199911050-00004
Czelusta, A J, et al. "A guide to immunotherapy of genital warts: focus on interferon and imiquimod." BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy vol. 11,5 (1999): 319-32. doi: https://doi.org/10.2165/00063030-199911050-00004
Czelusta AJ, Evans T, Arany I, Tyring SK. A guide to immunotherapy of genital warts: focus on interferon and imiquimod. BioDrugs. 1999 May;11(5):319-32. doi: 10.2165/00063030-199911050-00004. PMID: 18031142.
Copy Download .nbib Format: NLM
Do patients with clinically isolated syndrome benefit from treatment with interferon beta1b?.

Nature clinical practice. Neurology

Panitch H.
PMID: 17279081
Nat Clin Pract Neurol. 2007 Feb;3(2):80-1. doi: 10.1038/ncpneuro0397.

No abstract available.

Cite
Panitch H. Do patients with clinically isolated syndrome benefit from treatment with interferon beta1b?. Nat Clin Pract Neurol. 2007;3(2):80-1doi: 10.1038/ncpneuro0397.
Panitch, H. (2007). Do patients with clinically isolated syndrome benefit from treatment with interferon beta1b?. Nature clinical practice. Neurology, 3(2), 80-1. https://doi.org/10.1038/ncpneuro0397
Panitch, Hillel. "Do patients with clinically isolated syndrome benefit from treatment with interferon beta1b?." Nature clinical practice. Neurology vol. 3,2 (2007): 80-1. doi: https://doi.org/10.1038/ncpneuro0397
Panitch H. Do patients with clinically isolated syndrome benefit from treatment with interferon beta1b?. Nat Clin Pract Neurol. 2007 Feb;3(2):80-1. doi: 10.1038/ncpneuro0397. PMID: 17279081.
Copy Download .nbib Format: NLM
Dose and Frequency of Administration of Interferon-beta Affect its Efficacy in Multiple Sclerosis.

Clinical drug investigation

Sharief MK.
PMID: 17535068
Clin Drug Investig. 2003;23(9):551-9. doi: 10.2165/00044011-200323090-00001.

Data reviewed in this article demonstrate that both interferon-beta-1a (IFNbeta-1a) and interferon-beta-1b (IFNbeta-1b) show a dose-response relationship in multiple sclerosis at current clinical doses. Moreover, the efficacy of these therapies is probably dependent on their frequent administration to maintain...

Cite
Sharief MK. Dose and Frequency of Administration of Interferon-beta Affect its Efficacy in Multiple Sclerosis. Clin Drug Investig. 2003;23(9):551-9doi: 10.2165/00044011-200323090-00001.
Sharief, M. K. (2003). Dose and Frequency of Administration of Interferon-beta Affect its Efficacy in Multiple Sclerosis. Clinical drug investigation, 23(9), 551-9. https://doi.org/10.2165/00044011-200323090-00001
Sharief, Mohammed K. "Dose and Frequency of Administration of Interferon-beta Affect its Efficacy in Multiple Sclerosis." Clinical drug investigation vol. 23,9 (2003): 551-9. doi: https://doi.org/10.2165/00044011-200323090-00001
Sharief MK. Dose and Frequency of Administration of Interferon-beta Affect its Efficacy in Multiple Sclerosis. Clin Drug Investig. 2003;23(9):551-9. doi: 10.2165/00044011-200323090-00001. PMID: 17535068.
Copy Download .nbib Format: NLM
Evolving expectations around early management of multiple sclerosis.

Therapeutic advances in neurological disorders

Gold R, Wolinsky JS, Amato MP, Comi G.
PMID: 21179596
Ther Adv Neurol Disord. 2010 Nov;3(6):351-67. doi: 10.1177/1756285610385608.

Multiple sclerosis is a progressive inflammatory disease of the central nervous system. With prevention or at least delay of disease progression as a key target in the management of multiple sclerosis, current opinion on treatment encourages early intervention with...

Cite
Gold R, Wolinsky JS, Amato MP, et al. Evolving expectations around early management of multiple sclerosis. Ther Adv Neurol Disord. 2010;3(6):351-67doi: 10.1177/1756285610385608.
Gold, R., Wolinsky, J. S., Amato, M. P., & Comi, G. (2010). Evolving expectations around early management of multiple sclerosis. Therapeutic advances in neurological disorders, 3(6), 351-67. https://doi.org/10.1177/1756285610385608
Gold, Ralf, et al. "Evolving expectations around early management of multiple sclerosis." Therapeutic advances in neurological disorders vol. 3,6 (2010): 351-67. doi: https://doi.org/10.1177/1756285610385608
Gold R, Wolinsky JS, Amato MP, Comi G. Evolving expectations around early management of multiple sclerosis. Ther Adv Neurol Disord. 2010 Nov;3(6):351-67. doi: 10.1177/1756285610385608. PMID: 21179596; PMCID: PMC3002639.
Copy Download .nbib Format: NLM
Alemtuzumab versus interferon beta-1a in early multiple sclerosis.

Current neurology and neuroscience reports

Bourdette D, Yadav V.
PMID: 19664362
Curr Neurol Neurosci Rep. 2009 Sep;9(5):341-2. doi: 10.1007/s11910-009-0062-1.

No abstract available.

Cite
Bourdette D, Yadav V. Alemtuzumab versus interferon beta-1a in early multiple sclerosis. Curr Neurol Neurosci Rep. 2009;9(5):341-2doi: 10.1007/s11910-009-0062-1.
Bourdette, D., & Yadav, V. (2009). Alemtuzumab versus interferon beta-1a in early multiple sclerosis. Current neurology and neuroscience reports, 9(5), 341-2. https://doi.org/10.1007/s11910-009-0062-1
Bourdette, Dennis, and Yadav, Vijayshree. "Alemtuzumab versus interferon beta-1a in early multiple sclerosis." Current neurology and neuroscience reports vol. 9,5 (2009): 341-2. doi: https://doi.org/10.1007/s11910-009-0062-1
Bourdette D, Yadav V. Alemtuzumab versus interferon beta-1a in early multiple sclerosis. Curr Neurol Neurosci Rep. 2009 Sep;9(5):341-2. doi: 10.1007/s11910-009-0062-1. PMID: 19664362.
Copy Download .nbib Format: NLM
Patient satisfaction following transition from the original to the new formulation of subcutaneous interferon beta-1a in relapsing multiple sclerosis: a randomized, two-arm, open-label, Phase IIIb study.

Patient preference and adherence

Camu W, Hadjout K, Latour S, Pöhlau D, Masri S.
PMID: 20517473
Patient Prefer Adherence. 2010 May 13;4:127-33. doi: 10.2147/ppa.s10468.

OBJECTIVE: To assess satisfaction with the serum-free formulation of subcutaneous (sc) interferon (IFN) beta-1a among patients with relapsing multiple sclerosis (MS).METHODS: Patients with relapsing MS who had been receiving sc IFN beta-1a for at least 6 months, were transitioned...

Cite
Camu W, Hadjout K, Latour S, et al. Patient satisfaction following transition from the original to the new formulation of subcutaneous interferon beta-1a in relapsing multiple sclerosis: a randomized, two-arm, open-label, Phase IIIb study. Patient Prefer Adherence. 2010;4:127-33doi: 10.2147/ppa.s10468.
Camu, W., Hadjout, K., Latour, S., Pöhlau, D., & Masri, S. (2010). Patient satisfaction following transition from the original to the new formulation of subcutaneous interferon beta-1a in relapsing multiple sclerosis: a randomized, two-arm, open-label, Phase IIIb study. Patient preference and adherence, 4127-33. https://doi.org/10.2147/ppa.s10468
Camu, William, et al. "Patient satisfaction following transition from the original to the new formulation of subcutaneous interferon beta-1a in relapsing multiple sclerosis: a randomized, two-arm, open-label, Phase IIIb study." Patient preference and adherence vol. 4 (2010): 127-33. doi: https://doi.org/10.2147/ppa.s10468
Camu W, Hadjout K, Latour S, Pöhlau D, Masri S. Patient satisfaction following transition from the original to the new formulation of subcutaneous interferon beta-1a in relapsing multiple sclerosis: a randomized, two-arm, open-label, Phase IIIb study. Patient Prefer Adherence. 2010 May 13;4:127-33. doi: 10.2147/ppa.s10468. PMID: 20517473; PMCID: PMC2875722.
Copy Download .nbib Format: NLM
Review of interferon beta-1b in the treatment of early and relapsing multiple sclerosis.

Biologics : targets & therapy

Paolicelli D, Direnzo V, Trojano M.
PMID: 19707422
Biologics. 2009;3:369-76. Epub 2009 Jul 13.

Multiple sclerosis (MS) is the most common autoimmune illness of the central nervous system. For many years the inflammatory manifestations of MS were treated using only corticosteroids. Since the 1990s the results of several clinical trials with immunomodulatory agents...

Cite
Paolicelli D, Direnzo V, Trojano M. Review of interferon beta-1b in the treatment of early and relapsing multiple sclerosis. Biologics. 2009;3:369-76
Paolicelli, D., Direnzo, V., & Trojano, M. (2009). Review of interferon beta-1b in the treatment of early and relapsing multiple sclerosis. Biologics : targets & therapy, 3369-76.
Paolicelli, Damiano, et al. "Review of interferon beta-1b in the treatment of early and relapsing multiple sclerosis." Biologics : targets & therapy vol. 3 (2009): 369-76.
Paolicelli D, Direnzo V, Trojano M. Review of interferon beta-1b in the treatment of early and relapsing multiple sclerosis. Biologics. 2009;3:369-76. Epub 2009 Jul 13. PMID: 19707422; PMCID: PMC2726074.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 507 entries